ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.
The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.
advertisement
Arch declined to comment on the new fundraising.
Get unlimited access to award-winning journalism and exclusive events.
Subscribe Log In
Previous article：
I learned firsthand about improving diversity in clinical trials
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
Next article： New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
